Is AstraZeneca plc A Buy On $45bn Revenue Targets?

Will AstraZeneca plc’s (LON: AZN) drugs pipeline live up to expectations?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

In AstraZeneca‘s (LSE: AZN) (NYSE: AZN.US) defence of the recent Pfizer bid, one number was more critical than any other.

Pascal Soriot, the Astra chief executive, landed a flush right hand when he attached a valuation to the drugs pipeline, forecasting revenue gains of 75% in the coming decade, from $26bn to $45bn.

From that moment, Pfizer — much as happened to George Groves at Wembley this past weekend — lost the legs underneath itself.

The scrappy UK pharmaceutical firm — suddenly hailed for its innovation, after years of being anything but a frontrunner — retained its independence.

Not everyone was pleased by this. But, as far as I’m concerned, they’re wrong.

Product delivery

AstraZenecaBlackrock and Axa, the two largest shareholders in AstraZeneca, would like Pfizer to be brought to the discussion table again.

For long-term AstraZeneca investors, however, this would extract a brutal cost. Destructive synergies would serve to impede the best efforts of Astra’s scientists, and likely delay the delivery of new products.

It’s difficult for a scientist to apply complete focus if they don’t know whether their job is safe. Pfizer’s keenest interest (in addition to huge tax savings) was in Astra’s promising oncology treatments. These treatments can now be delivered more quickly.

New cancer treatments

Earlier this week AstraZeneca reported positive trial data for two of its lung cancer treatments AZD9291 and MEDI4736. Mr Soriot, who has plenty of doubters, needs to convince those who are sceptical that his revenue projections are more than hot air.

In Soriot’s words, these drugs, known as immunotherapies, “demonstrate potential to transform the way cancer is treated”.

Immunotherapies stimulate the body’s immune system to fight cancer, whereas rival healthcare companies have opted for checkpoint inhibitors, which flag up cancer cells that the body has mistaken as healthy and then the immune system attacks.

A $10bn market

Could MEDI4736 be the next blockbuster drug for AstraZeneca? Analysts have suggested the immunotherapy market could be worth more than $10bn a year, and were Astra to take a piece of that then shareholders would have reason to smile.

The field is competitive but, for all of AstraZeneca’s strides, the firm is a latecomer in the area, and the effectiveness of its treatments against similar products has yet to be proven.

Time matters here. Often, perhaps most pertinently for new shareholders, tardiness might be an irrelevance. The market only looks forward, and if a company has low hanging fruit to grab, that can be a selling point.

But AstraZeneca needs marketplace primacy to achieve its revenue targets.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Mark does not own shares in AstraZeneca.

More on Company Comment

Hand of person putting wood cube block with word VALUE on wooden table
Company Comment

Value has been building behind the Diageo share price

Despite the business growing, the Diageo share price first reached its current level just over 19 months ago and hasn't…

Read more »

Older couple walking in park
Investing Articles

5 stocks to buy for high and rising dividend income

I can see a host of shares to buy on the FTSE 100 offering me exceptional levels of income. Here…

Read more »

Young mixed-race woman looking out of the window with a look of consternation on her face
Investing Articles

I don’t care if FTSE 100 shares fall further, I’m buying them today

I'm happy to go shopping for FTSE 100 shares today, even though I accept that they could have further to…

Read more »

Happy young female stock-picker in a cafe
Investing Articles

Rolls-Royce shares are down 18% in a month and I’m finally going to buy them

Investors who bought Rolls-Royce shares have been repeatedly disappointed, but I'm willing to take a chance on them before they…

Read more »

Storytelling image of a multiethnic senior couple in love - Elderly married couple dating outdoors, love emotions and feelings
Investing Articles

How I’d invest £10k in a Stocks and Shares ISA today

Now looks like a good time to buy cheap FTSE 100 shares inside a Stocks and Shares ISA. These are…

Read more »

Black father holding daughter in a field of cows
Investing Articles

Today’s financial crisis is the perfect moment to buy cheap shares

I'm building a portfolio of FTSE 100 stocks by purchasing cheap shares whenever I see an opportunity. There's a good…

Read more »

Long-term vs short-term investing concept on a staircase
Investing Articles

I’d buy Tesco shares in October to bag their 5.4% yield 

Tesco shares have fallen lately but I think this makes them attractively valued for a dividend stock I would aim…

Read more »

Young mixed-race woman looking out of the window with a look of consternation on her face
Investing Articles

I would do anything to hold Diageo in my portfolio (but I won’t do that)

Diageo is one of my favourite stocks on the entire FTSE 100 and I'd love to hold it, but one…

Read more »